Total Payments
$545.81
2024 Payments
$341.77
Companies
13
Transactions
19
Medicare Patients
4,155
Medicare Billing
$637,456
Payment Breakdown by Category
Food & Beverage$501.44 (91.9%)
Education$44.37 (8.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $501.44 | 17 | 91.9% |
| Education | $44.37 | 2 | 8.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $124.46 | 1 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $94.44 | 1 | $0 (2017) |
| PFIZER INC. | $91.57 | 6 | $0 (2024) |
| Janssen Biotech, Inc. | $38.23 | 1 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $32.45 | 1 | $0 (2024) |
| Celgene Corporation | $30.79 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $27.21 | 1 | $0 (2024) |
| Merck Sharp & Dohme LLC | $23.54 | 1 | $0 (2024) |
| Exelixis Inc. | $22.78 | 1 | $0 (2024) |
| ARRAY BIOPHARMA INC | $19.48 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $341.77 | 10 | Astellas Pharma US Inc ($124.46) |
| 2023 | $49.19 | 3 | PFIZER INC. ($20.25) |
| 2022 | $16.39 | 1 | Celgene Corporation ($16.39) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2017 | $126.54 | 4 | Valeant Pharmaceuticals North America LLC ($94.44) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.40 | General |
| Category: Hematology | ||||||
| 11/14/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $19.48 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | E.R. Squibb & Sons, L.L.C. | — | Education | In-kind items and services | $32.45 | General |
| 10/24/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $38.23 | General |
| Category: Oncology | ||||||
| 09/10/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $124.46 | General |
| Category: Oncology | ||||||
| 08/29/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 05/24/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $21.56 | General |
| Category: ONCOLOGY | ||||||
| 03/28/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: ONCOLOGY | ||||||
| 02/08/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $27.21 | General |
| Category: Oncology | ||||||
| 11/09/2023 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: Oncology | ||||||
| 10/31/2023 | PFIZER INC. | INLYTA (Drug), XTANDI | Food and Beverage | In-kind items and services | $20.25 | General |
| Category: ONCOLOGY | ||||||
| 05/03/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $12.97 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $16.39 | General |
| Category: Hematology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 11/01/2017 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $10.70 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 04/05/2017 | PFIZER INC. | ELIQUIS (Drug), CHANTIX | Food and Beverage | In-kind items and services | $10.70 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 03/28/2017 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $10.70 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 01/31/2017 | Valeant Pharmaceuticals North America LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $94.44 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 981 | 1,821 | $640,059 | $153,670 |
| 2022 | 6 | 867 | 1,684 | $471,439 | $140,495 |
| 2021 | 6 | 1,083 | 2,072 | $594,895 | $183,945 |
| 2020 | 9 | 1,224 | 2,247 | $601,260 | $159,345 |
Total Patients
4,155
Total Services
7,824
Medicare Billing
$637,456
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 538 | 1,207 | $351,237 | $85,235 | 24.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 164 | 308 | $131,091 | $33,463 | 25.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 173 | 173 | $106,222 | $21,738 | 20.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 49 | 55 | $31,790 | $7,294 | 22.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 53 | $14,999 | $4,814 | 32.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 24 | 25 | $4,720 | $1,127 | 23.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 487 | 1,130 | $268,974 | $78,671 | 29.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 165 | 312 | $99,152 | $33,493 | 33.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 123 | 123 | $59,058 | $16,115 | 27.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 45 | 52 | $30,056 | $7,736 | 25.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 26 | 44 | $10,478 | $3,497 | 33.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 21 | 23 | $3,721 | $984.05 | 26.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 533 | 1,170 | $269,100 | $83,538 | 31.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 233 | 541 | $181,002 | $58,561 | 32.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 167 | 167 | $80,494 | $23,236 | 28.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 60 | 71 | $41,038 | $10,991 | 26.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 29 | 55 | $12,925 | $4,293 | 33.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 61 | 68 | $10,336 | $3,326 | 32.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 518 | 1,295 | $291,375 | $74,903 | 25.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 204 | 364 | $118,941 | $30,601 | 25.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 182 | 182 | $85,904 | $23,095 | 26.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 91 | 108 | $60,801 | $17,080 | 28.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 49 | 95 | $21,850 | $7,808 | 35.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 91 | 103 | $15,347 | $3,562 | 23.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 19 | 21 | $4,725 | $1,737 | 36.8% |
About Dr. Andrew Schreiber, MD
Dr. Andrew Schreiber, MD is a Medical Oncology healthcare provider based in Wilmington, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689600058.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Schreiber, MD has received a total of $545.81 in payments from pharmaceutical and medical device companies, with $341.77 received in 2024. These payments were reported across 19 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($501.44).
As a Medicare-enrolled provider, Schreiber has provided services to 4,155 Medicare beneficiaries, totaling 7,824 services with total Medicare billing of $637,456. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology, Hematology & Oncology
- Location Wilmington, NC
- Active Since 06/25/2006
- Last Updated 01/10/2026
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1689600058
Products in Payments
- Xtandi (Drug) $124.46
- PROVENGE (Drug) $94.44
- INLYTA (Drug) $59.47
- ERLEADA (Drug) $38.23
- REBLOZYL (Biological) $30.79
- PLUVICTO (Drug) $27.21
- KEYTRUDA (Biological) $23.54
- CABOMETYX (Drug) $22.78
- ELIQUIS (Drug) $21.40
- BRAFTOVI (Drug) $19.48
- Nubeqa (Drug) $15.97
- ALUNBRIG (Drug) $12.97
- CHANTIX (Drug) $10.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Wilmington
Gerard Kennealey, Md, MD
Medical Oncology — Payments: $563,502
Medical Oncology $563,502
Justin Markow, Do, DO
Medical Oncology — Payments: $400.68
Medical Oncology $400.68
Dr. Victor Sandor, Md, MD
Medical Oncology — Payments: $300.67
Medical Oncology $300.67
Douglas Testori, D.o, D.O
Medical Oncology — Payments: $45.32
Medical Oncology $45.32
William Mcnulty, Md, MD
Medical Oncology
Medical Oncology